What it does:10x Genomics makes software for researchers to perform single cell and whole genome sequencing. Its software can be used for immunotherapy and cell therapy research in cancer patients or patients with rare genetic disorders. The Silicon Valley-based company was founded by Serge Saxonov, formerly the founding director of research at consumer genetics company 23andMe.
Deal details: SoftBank participated in the company s $125 million Series D funding round in 2018 that valued the company at $1.25 billion. It went public in September 2019 and was valued above $3.6 billion in its debut. SoftBank is no longer invested in 10x Genomics.
Other investors: Venrock, Fidelity International, Foresight Capital Management, and Paladin Capital Group
/PRNewswire/ Turn Biotechnologies, a company developing medicines for currently untreatable age-related conditions, announced that it has acquired the.
Shanda Group sold half its CHS stock in past two months
Modern Healthcare Illustration / Getty Images
A major Community Health Systems shareholder has sold off half its stock over the past two months, cashing in on a price surge that followed an unexpected earning rebound and news that the company s CEO is stepping down.
Singapore-based Shanda Group, led by billionaire investor Tianqiao Chen, sold nearly $110 million worth of common stock in the investor-owned hospital chain across a series of transactions in November and December, bringing its stake down to 12.2% of the company s outstanding shares, according to the Securities and Exchange Commission. That s down from 24% in November, a stake Shanda had maintained since 2018.